Cationic Nanomaterials for Autoimmune Diseases Therapy

Abstract

Cationic nanomaterials are defined as nanoscale structures smaller than 100 nm bearing positive charges. They have been investigated to apply to many aspects including clinical diagnosis, gene delivery, drug delivery, and tissue engineering for years. Recently, a novel concept has been made to use cationic nanomaterials as cell-free nucleic acid scavengers and inhibits the inflammatory responses in autoimmune diseases. Here, we highlighted different types of cationic materials which have the potential for autoimmune disease treatment and reviewed the strategy for autoimmune diseases therapy based on cationic nanoparticles. This review will also demonstrate the challenges and possible solutions that are encountered during the development of cationic materials-based therapeutics for autoimmune diseases.

Transverse myelitis associated with systemic lupus erythematosus (SLE-TM): A review article

“…Recently, cationic nanomaterials have been investigated for inhibiting inflammatory responses in autoimmune disease with some potential in mouse models of SLE. 54 Similarly small molecule compounds such as K-7174 have shown to attenuate NPSLE manifestations in lupus-prone mice. 55 These again might hold promise for future treatments in NPSLE and SLE-TM.…”

Pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus: A review

“…Although the current application is still in its infancy and relevant studies are comparatively limited, it has shown potential in murine models of SLE. We may also look forward to its upcoming use in the treatment of NPSLE ( Xie et al, 2021 ).…”

Targeting Lymph Nodes for Systemic Immunosuppression Using Cell‐Free‐DNA‐Scavenging And cGAS‐Inhibiting Nanomedicine‐In‐Hydrogel for Rheumatoid Arthritis Immunotherapy

“…Towards this end, current approaches include systemic administration of cfDNA‐scavenging cationic biomaterials, which, however, are associated with concerns over the toxicity caused by the nonspecific cationic biomaterials. [ 19–21 ]…”

“…Towards this end, current approaches include systemic administration of cfDNAscavenging cationic biomaterials, which, however, are associated with concerns over the toxicity caused by the nonspecific cationic biomaterials. [19][20][21] Lymph nodes (LNs) are secondary lymphoid tissues that orchestrate a wide range of immune responses and maintain immune homeostasis. [22,23] Clinical studies indicated that 82% of RA patients show symptoms of lymphadenomegaly (enlarged LNs), which is associated with RA severity and treatment responsiveness.…”